SEC Form 4 · accession 0001250853-18-000150
LIXTE BIOTECHNOLOGY HOLDINGS, INC. · NMAD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Dec 7, 2018
Accepted (ET)
Dec 11, 2018 · 7:49 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001335105
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 7, 2018 | P | 1,260,000 | $0.50 | A | 6,110,000 | I | By the Arthur and Jane Riggs 1990 Revocable Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrants to Purchase Common Stock | $1.00 | Dec 7, 2018 | P | 1,260,000 | A | Dec 7, 2018 | Nov 30, 2022 | Common Stock | 1,260,000 | 1,260,000 | I |
Explanation of responses
- F1The reporting person acquired 1,260,000 Units, each Unit consisting of one share of Common Stock and a four year warrant at an exercise price of $1.00 per share. The purchase price for a Unit was $0.50 per Unit.